Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Valerius

Showing results (1-10 of 119) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2010
Fcgamma receptor polymorphisms as biomarkers for epidermal growth factor receptor antibodiesThomas Valerius
Blood|March 20, 2025
Complementing CD20 antibodies' effector functionsJeanette Leusen, Thomas Valerius
Oncoimmunology|June 14, 2013
EGFR expression levels affect the mode of action of EGFR-targeting monoclonal antibodiesStefanie Derer, Stefan Lohse, Thomas Valerius
Mabs|January 14, 2010
Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodiesMatthias Peipp, Michael Dechant, Thomas Valerius
Current Opinion in Immunology|July 1, 2008
Effector mechanisms of therapeutic antibodies against ErbB receptorsMatthias Peipp, Michael Dechant, Thomas Valerius
Seminars in Oncology|August 27, 2003
HLA class II antibodies in the treatment of hematologic malignanciesMichael Dechant, Joerg Bruenke, Thomas Valerius
Nature Reviews. Clinical Oncology|December 22, 2018
Myeloid immune-checkpoint inhibition enters the clinical stageTimo K van den Berg, Thomas Valerius
The New England Journal of Medicine|February 1, 2019
CD47 Blockade and Rituximab in Non-Hodgkin’s LymphomaThomas Valerius, Thies Rösner, Jeanette H W Leusen
Journal of Immunology (Baltimore, Md. : 1950)|March 22, 2002
Intracellular domains of target antigens influence their capacity to trigger antibody-dependent cell-mediated cytotoxicityKlaus Tiroch, Bernhard Stockmeyer, Carola Frank, et al.
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|October 27, 2017
Antibody Isotypes for Tumor ImmunotherapyAnna Kretschmer, Ralf Schwanbeck, Thomas Valerius, et al.
Pageof 12

Showing results (1-10 of 119) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2010
Fcgamma receptor polymorphisms as biomarkers for epidermal growth factor receptor antibodiesThomas Valerius
Blood|March 20, 2025
Complementing CD20 antibodies' effector functionsJeanette Leusen, Thomas Valerius
Oncoimmunology|June 14, 2013
EGFR expression levels affect the mode of action of EGFR-targeting monoclonal antibodiesStefanie Derer, Stefan Lohse, Thomas Valerius
Mabs|January 14, 2010
Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodiesMatthias Peipp, Michael Dechant, Thomas Valerius
Current Opinion in Immunology|July 1, 2008
Effector mechanisms of therapeutic antibodies against ErbB receptorsMatthias Peipp, Michael Dechant, Thomas Valerius
Seminars in Oncology|August 27, 2003
HLA class II antibodies in the treatment of hematologic malignanciesMichael Dechant, Joerg Bruenke, Thomas Valerius
Nature Reviews. Clinical Oncology|December 22, 2018
Myeloid immune-checkpoint inhibition enters the clinical stageTimo K van den Berg, Thomas Valerius
The New England Journal of Medicine|February 1, 2019
CD47 Blockade and Rituximab in Non-Hodgkin’s LymphomaThomas Valerius, Thies Rösner, Jeanette H W Leusen
Journal of Immunology (Baltimore, Md. : 1950)|March 22, 2002
Intracellular domains of target antigens influence their capacity to trigger antibody-dependent cell-mediated cytotoxicityKlaus Tiroch, Bernhard Stockmeyer, Carola Frank, et al.
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|October 27, 2017
Antibody Isotypes for Tumor ImmunotherapyAnna Kretschmer, Ralf Schwanbeck, Thomas Valerius, et al.
Pageof 12